<< Back

October 11-15, 2023, AACR- NCI- EORCT International Conference On Molecular Targets And Cancer Therapeutics

1) Identification of Paralogue Selective Degraders Of SMARCA2 And SMARCA4 for the Treatment of Various Cancers
2) Discovery of Potent and Paralogue Selective PROTAC Degraders of CBP or P300 Proteins for the Treatments Of Various Cancers
3) Potent Anti Tumor Activity of a Selective and Orally Bioavailable Reversible Covalent CDK12 Inhibitor
4) Discovery of AUR-112, a Novel MALT1 Protease Inhibitor for the Treatment of B Cell Lymphoma.